TY - JOUR
T1 - Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas
AU - Yam, Clinton
AU - Landsburg, Daniel J.
AU - Nead, Kevin T.
AU - Lin, Xinyi
AU - Mato, Anthony R.
AU - Svoboda, Jakub
AU - Loren, Alison W.
AU - Frey, Noelle V.
AU - Stadtmauer, Edward A.
AU - Porter, David L.
AU - Schuster, Stephen J.
AU - Nasta, Sunita D.
N1 - Publisher Copyright:
© 2016 Wiley Periodicals, Inc.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Patients with peripheral T cell lymphomas (PTCL) generally have a poor prognosis when treated with conventional chemotherapy. Consolidation with autologous stem cell transplantation (ASCT) has been reported to improve progression-free survival. However, these studies have not compared consolidative ASCT with active observation in patients with PTCL achieving first complete remission (CR1) following induction chemotherapy. We conducted a retrospective analysis of PTCL patients treated at the University of Pennsylvania between 1/1/2007 and 12/31/2014. Patients with cutaneous T cell lymphoma, concurrent B cell lymphomas, and anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK-positive ALCL) were excluded from the study. We compared progression-free survival for patients who underwent ASCT in CR1 following CHOP-like induction regimens and patients who underwent active observation during CR1. 48 patients met all inclusion and exclusion criteria and underwent either active observation (28 patients) or consolidative ASCT (20 patients) in CR1. The 1-year cumulative incidence of relapse in the observation and ASCT groups was 50% (95% confidence interval [CI]: 30–67%) and 46% (95% CI: 23–67%), respectively (P = 0.55). Median progression-free survival in the observation and ASCT groups was 15.8 and 12.8 months, respectively (log rank, P = 0.79). Estimated 3-year progression-free survival in the observation and ASCT groups was 37 and 41%, respectively. In conclusion, for PTCL patients achieving CR1 following CHOP-like induction chemotherapy, ASCT does not appear to improve progression-free survival compared to active observation. This finding should be confirmed in a larger, prospective study. Am. J. Hematol. 91:672–676, 2016.
AB - Patients with peripheral T cell lymphomas (PTCL) generally have a poor prognosis when treated with conventional chemotherapy. Consolidation with autologous stem cell transplantation (ASCT) has been reported to improve progression-free survival. However, these studies have not compared consolidative ASCT with active observation in patients with PTCL achieving first complete remission (CR1) following induction chemotherapy. We conducted a retrospective analysis of PTCL patients treated at the University of Pennsylvania between 1/1/2007 and 12/31/2014. Patients with cutaneous T cell lymphoma, concurrent B cell lymphomas, and anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK-positive ALCL) were excluded from the study. We compared progression-free survival for patients who underwent ASCT in CR1 following CHOP-like induction regimens and patients who underwent active observation during CR1. 48 patients met all inclusion and exclusion criteria and underwent either active observation (28 patients) or consolidative ASCT (20 patients) in CR1. The 1-year cumulative incidence of relapse in the observation and ASCT groups was 50% (95% confidence interval [CI]: 30–67%) and 46% (95% CI: 23–67%), respectively (P = 0.55). Median progression-free survival in the observation and ASCT groups was 15.8 and 12.8 months, respectively (log rank, P = 0.79). Estimated 3-year progression-free survival in the observation and ASCT groups was 37 and 41%, respectively. In conclusion, for PTCL patients achieving CR1 following CHOP-like induction chemotherapy, ASCT does not appear to improve progression-free survival compared to active observation. This finding should be confirmed in a larger, prospective study. Am. J. Hematol. 91:672–676, 2016.
UR - http://www.scopus.com/inward/record.url?scp=84973911828&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84973911828&partnerID=8YFLogxK
U2 - 10.1002/ajh.24372
DO - 10.1002/ajh.24372
M3 - Article
C2 - 27012928
AN - SCOPUS:84973911828
SN - 0361-8609
VL - 91
SP - 672
EP - 676
JO - American journal of hematology
JF - American journal of hematology
IS - 7
ER -